Jubilant Pharmova Ltd
NSE:JUBLPHARMA

Watchlist Manager
Jubilant Pharmova Ltd Logo
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Watchlist
Price: 1 097.4 INR 2.75% Market Closed
Market Cap: 174.8B INR
Have any thoughts about
Jubilant Pharmova Ltd?
Write Note

Jubilant Pharmova Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jubilant Pharmova Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Pre-Tax Income
â‚ą6.9B
CAGR 3-Years
-13%
CAGR 5-Years
-2%
CAGR 10-Years
13%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Pre-Tax Income
â‚ą72.3B
CAGR 3-Years
35%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Pre-Tax Income
â‚ą61.3B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
15%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Pre-Tax Income
â‚ą128.4B
CAGR 3-Years
22%
CAGR 5-Years
18%
CAGR 10-Years
5%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Pre-Tax Income
â‚ą25.8B
CAGR 3-Years
15%
CAGR 5-Years
30%
CAGR 10-Years
9%
M
Mankind Pharma Ltd
NSE:MANKIND
Pre-Tax Income
â‚ą24B
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jubilant Pharmova Ltd
Glance View

Market Cap
173.8B INR
Industry
Pharmaceuticals

Once rooted as a modest family business, Jubilant Pharmova Ltd. has evolved into a global powerhouse in the pharmaceutical and life sciences industry. Founded by the visionary Bhartia family, the company has sprawled across continents, transforming healthcare landscapes with its robust product portfolio. Jubilant Pharmova's journey is one painted with strategic diversification, cleverly balancing risk and driving sustainable growth. At its core, the company operates through three primary segments: Pharmaceuticals, Contract Research and Development Services, and Proprietary Drug Discovery. Each arm serves as a critical piece in the company's strategic mosaic, enhancing its resilience amid the ever-fluctuating pharmaceutical market dynamics. Underpinning Jubilant Pharmova's business model is its Pharmaceuticals segment, which churns a significant portion of its revenue. The company manufactures and sells an array of pharmaceutical products, including generics and specialty pharmaceuticals, which cater to multiple therapeutic areas. Further driving its financial engine is the Contract Research and Development Service segment, which offers outsourced R&D solutions to a host of pharmaceutical majors—a sector that has witnessed burgeoning demand alongside escalating R&D costs globally. On the innovation frontier, the Proprietary Drug Discovery segment embarks on uncharted territories, seeking novel drugs and solutions, paving the path for the future. Such a diversified approach not only positions Jubilant Pharmova as a formidable entity in the pharmaceutical domain but also provides a cushion against industry-specific headwinds, reinforcing its long-term sustainability.

JUBLPHARMA Intrinsic Value
904.27 INR
Overvaluation 18%
Intrinsic Value
Price

See Also

What is Jubilant Pharmova Ltd's Pre-Tax Income?
Pre-Tax Income
6.9B INR

Based on the financial report for Sep 30, 2024, Jubilant Pharmova Ltd's Pre-Tax Income amounts to 6.9B INR.

What is Jubilant Pharmova Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
13%

Over the last year, the Pre-Tax Income growth was 1 420%. The average annual Pre-Tax Income growth rates for Jubilant Pharmova Ltd have been -13% over the past three years , -2% over the past five years , and 13% over the past ten years .

Back to Top